Header

UZH-Logo

Maintenance Infos

Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains


Abstract

Targeting bromodomains (BRDs) of the bromo-and-extra-terminal (BET) family offers opportunities for therapeutic intervention in cancer and other diseases. Here, we profile the interactomes of BRD2, BRD3, BRD4, and BRDT following treatment with the pan-BET BRD inhibitor JQ1, revealing broad rewiring of the interaction landscape, with three distinct classes of behavior for the 603 unique interactors identified. A group of proteins associate in a JQ1-sensitive manner with BET BRDs through canonical and new binding modes, while two classes of extra-terminal (ET)-domain binding motifs mediate acetylation-independent interactions. Last, we identify an unexpected increase in several interactions following JQ1 treatment that define negative functions for BRD3 in the regulation of rRNA synthesis and potentially RNAPII-dependent gene expression that result in decreased cell proliferation. Together, our data highlight the contributions of BET protein modules to their interactomes allowing for a better understanding of pharmacological rewiring in response to JQ1.

Abstract

Targeting bromodomains (BRDs) of the bromo-and-extra-terminal (BET) family offers opportunities for therapeutic intervention in cancer and other diseases. Here, we profile the interactomes of BRD2, BRD3, BRD4, and BRDT following treatment with the pan-BET BRD inhibitor JQ1, revealing broad rewiring of the interaction landscape, with three distinct classes of behavior for the 603 unique interactors identified. A group of proteins associate in a JQ1-sensitive manner with BET BRDs through canonical and new binding modes, while two classes of extra-terminal (ET)-domain binding motifs mediate acetylation-independent interactions. Last, we identify an unexpected increase in several interactions following JQ1 treatment that define negative functions for BRD3 in the regulation of rRNA synthesis and potentially RNAPII-dependent gene expression that result in decreased cell proliferation. Together, our data highlight the contributions of BET protein modules to their interactomes allowing for a better understanding of pharmacological rewiring in response to JQ1.

Statistics

Citations

Dimensions.ai Metrics
12 citations in Web of Science®
13 citations in Scopus®
Google Scholar™

Altmetrics

Downloads

67 downloads since deposited on 24 Jan 2019
63 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Journal Article, refereed, original work
Communities & Collections:04 Faculty of Medicine > University Hospital Zurich > Clinic for Gynecology
Dewey Decimal Classification:610 Medicine & health
Date:1 February 2019
Deposited On:24 Jan 2019 09:10
Last Modified:01 Jan 2020 16:39
Publisher:Cell Press (Elsevier)
ISSN:1097-2765
OA Status:Green
Free access at:PubMed ID. An embargo period may apply.
Publisher DOI:https://doi.org/10.1016/j.molcel.2018.11.006
PubMed ID:30554943

Download

Green Open Access

Download PDF  'Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains'.
Preview
Content: Published Version
Filetype: PDF
Size: 10MB
View at publisher
Licence: Creative Commons: Attribution 4.0 International (CC BY 4.0)
Download PDF  'Interactome Rewiring Following Pharmacological Targeting of BET Bromodomains'.
Preview
Content: Accepted Version
Language: English
Filetype: PDF
Size: 3MB